1
|
Takeshita T, Iwamoto T, Niikura N, Watanabe K, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S. Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing. ESMO Open 2024; 9:102385. [PMID: 38387111 PMCID: PMC11076976 DOI: 10.1016/j.esmoop.2024.102385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 01/18/2024] [Accepted: 01/22/2024] [Indexed: 02/24/2024] Open
Abstract
BACKGROUND The FUTURE trial (UMIN000029294) demonstrated the safety and efficacy of adding palbociclib after fulvestrant resistance in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced and metastatic breast cancer (ABC/MBC). In this planned sub-study, cancer panel sequencing of cell-free DNA (cfDNA) was utilized to explore prognostic and predictive biomarkers for further palbociclib treatment following fulvestrant resistance. MATERIALS AND METHODS Herein, 149 cfDNA samples from 65 patients with fulvestrant-resistant disease were analysed at the time of palbociclib addition after fulvestrant resistance (baseline), on day 15 of cycle 1, and at the end of treatment using the assay for identifying diverse mutations in 34 cancer-related genes. RESULTS During the course of treatment, mutations in ESR1, PIK3CA, FOXA1, RUNX1, TBX3, and TP53 were the most common genomic alterations observed. Analysis of genomic mutations revealed that before fulvestrant introduction, baseline PIK3CA mutations were marginally lower in metastatic aromatase inhibitor (AI)-treated patients compared to adjuvant AI-treated patients (P = 0.063). Baseline PIK3CA mutations were associated with poorer progression-free survival [hazard ratio: 1.62, P = 0.04]. Comparative analysis between baseline and early-changing gene mutations identified poor prognostic factors including early-changing MAP3K1 mutations (hazard ratio: 4.66, P = 0.04), baseline AR mutations (hazard ratio: 3.53, P = 0.04), and baseline PIK3CA mutations (hazard ratio: 3.41, P = 0.02). Notably, the relationship between ESR1 mutations and mutations in PIK3CA, MAP3K1, and TP53 weakened as treatment progressed. Instead, PIK3CA mutations became correlated with TP53 and FOXA1 mutations. CONCLUSIONS Cancer panel testing for cfDNA identified prognostic and predictive biomarkers for palbociclib add-on therapy after acquiring fulvestrant resistance in patients with HR+/HER2- ABC/MBC.
Collapse
Affiliation(s)
- T Takeshita
- Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto.
| | - T Iwamoto
- Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Kurashiki
| | - N Niikura
- Department of Breast Oncology, Tokai University School of Medicine, Isehara, Kanagawa
| | - K Watanabe
- Department of Breast Surgery, Hokkaido Cancer Center, Sapporo, Hokkaido
| | - Y Kikawa
- Department of Breast Surgery, Kansai Medical University Hospital, Hirakata, Osaka
| | - K Kobayashi
- Department of Medical Oncology, Saitama Red Cross Hospital, Chuo-ku, Saitama
| | - N Iwakuma
- Breast Center, Department of Breast Surgery, NHO Kyushu Medical Center, Fukuoka
| | - T Okamura
- Department of Breast Oncology, Tokai University School of Medicine, Isehara, Kanagawa
| | - H Tada
- Division of Breast and Endocrine Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi
| | - S Ozaki
- Department of Gastrointestinal and Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima
| | - T Okuno
- Department of Breast Surgery, Kobe City Nishi-Kobe Medical Center, Kobe, Hyogo
| | - U Toh
- Department of Breast Surgery, Kurume University Hospital, Kurume, Fukuoka
| | - Y Yamamoto
- Department of Breast and Endocrine Surgery, Kumamoto University Hospital, Kumamoto
| | - M Tsuneizumi
- Department of Breast Surgery, Shizuoka General Hospital, Shizuoka
| | - H Ishiguro
- Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Saitama
| | - N Masuda
- Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya
| | - S Saji
- Department of Medical Oncology, Fukushima Medical University, School of Medicine, Fukushima, Japan
| |
Collapse
|
2
|
Strasser P, Fukumura S, Iwai R, Kanda S, Kawamura S, Kitaguchi M, Nishimura S, Seo S, Shimizu HM, Shimomura K, Tada H, Torii HA. Improved Measurements of Muonic Helium Ground-State Hyperfine Structure at a Near-Zero Magnetic Field. Phys Rev Lett 2023; 131:253003. [PMID: 38181354 DOI: 10.1103/physrevlett.131.253003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 10/12/2023] [Accepted: 11/15/2023] [Indexed: 01/07/2024]
Abstract
Muonic helium atom hyperfine structure (HFS) measurements are a sensitive tool to test the three-body atomic system and bound-state quantum electrodynamics theory, and determine fundamental constants of the negative muon magnetic moment and mass. The world's most intense pulsed negative muon beam at the Muon Science Facility of the Japan Proton Accelerator Research Complex allows improvement of previous measurements and testing further CPT invariance by comparing the magnetic moments and masses of positive and negative muons (second-generation leptons). We report new ground-state HFS measurements of muonic helium-4 atoms at a near-zero magnetic field, performed for the first time using a small admixture of CH_{4} as an electron donor to form neutral muonic helium atoms efficiently. Our analysis gives Δν=4464.980(20) MHz (4.5 ppm), which is more precise than both previous measurements at weak and high fields. The muonium ground-state HFS was also measured under the same conditions to investigate the isotopic effect on the frequency shift due to the gas density dependence in He with CH_{4} admixture and compared with previous studies. Muonium and muonic helium can be regarded as light and heavy hydrogen isotopes with an isotopic mass ratio of 36. No isotopic effect was observed within the current experimental precision.
Collapse
Affiliation(s)
- P Strasser
- Muon Science Laboratory, Institute of Materials Structure Science (IMSS), High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
- Muon Science Section, Materials and Life Science Division, J-PARC Center, 2-4 Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
- Materials Structure Science Program, Graduate Institute for Advanced Studies, SOKENDAI, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S Fukumura
- Department of Physics, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
| | - R Iwai
- Muon Science Laboratory, Institute of Materials Structure Science (IMSS), High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S Kanda
- Muon Science Laboratory, Institute of Materials Structure Science (IMSS), High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
- Muon Science Section, Materials and Life Science Division, J-PARC Center, 2-4 Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
- Materials Structure Science Program, Graduate Institute for Advanced Studies, SOKENDAI, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - S Kawamura
- Department of Physics, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
| | - M Kitaguchi
- Department of Physics, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
- Kobayashi-Maskawa Institute, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan
| | - S Nishimura
- Muon Science Laboratory, Institute of Materials Structure Science (IMSS), High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
- Muon Science Section, Materials and Life Science Division, J-PARC Center, 2-4 Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - S Seo
- Graduate School of Arts and Sciences, The University of Tokyo, 3-8-1 Komaba, Meguro, Tokyo 153-8902, Japan
| | - H M Shimizu
- Department of Physics, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
| | - K Shimomura
- Muon Science Laboratory, Institute of Materials Structure Science (IMSS), High Energy Accelerator Research Organization (KEK), 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
- Muon Science Section, Materials and Life Science Division, J-PARC Center, 2-4 Shirakata, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
- Materials Structure Science Program, Graduate Institute for Advanced Studies, SOKENDAI, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan
| | - H Tada
- Department of Physics, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
| | - H A Torii
- School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|
3
|
Yamanaka H, Sawaragi E, Nakano T, Katayama Y, Ito T, Tada H, Hidaka Y, Morita S, Funakoshi C, Kinoshita A, Watanabe M, Tsuge I, Katsube M, Sakamoto M, Yamaoka T, Morimoto N. A high-hydrostatic pressure device for nevus tissue inactivation and dermal regeneration for reconstructing skin defects after giant congenital melanocytic nevus excision: a clinical trial. Regen Ther 2023; 24:167-173. [PMID: 37448852 PMCID: PMC10338193 DOI: 10.1016/j.reth.2023.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 06/08/2023] [Accepted: 06/24/2023] [Indexed: 07/15/2023] Open
Abstract
Background A novel treatment has been developed to reconstruct large skin defects caused by the excision of giant congenital melanocytic nevi. It involves the reimplantation of high-hydrostatic pressurized nevus tissue as a cell-inactivated autologous scaffold for dermal regeneration, followed by the implantation of cultured epithelial autografts on the regenerated dermis. Because this treatment has shown promise in a first-in-human clinical trial which used a prototype pressure machine, a novel pressure device was specifically designed for clinical use. Methods In a prospective investigator-initiated clinical trial involving three patients, we evaluated the safety and efficacy of the skin regeneration treatment using a pressure device. All three patients underwent surgical excision of the nevus tissue, primary reimplantation of the inactivated nevus tissue, and secondary implantation of cultured epithelial autografts. Results Engraftment of inactivated nevus tissue and cultured epithelial autografts was successful in all three cases, with over 90% epithelialization at 8 weeks post-surgery. No serious adverse events or device malfunction were observed during the trial. Conclusion The novel pressure device safely and effectively enabled dermal regeneration using the nevus tissue as an autologous scaffold. This innovative approach offers several advantages, including reduced invasiveness due to minimal sacrifice of normal skin for skin grafting and high curative potential resulting from full-thickness removal of the nevus tissue.
Collapse
Affiliation(s)
- Hiroki Yamanaka
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Eiichi Sawaragi
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Takashi Nakano
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Yasuhiro Katayama
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Tatsuya Ito
- Regulatory Science and Pharmaceutical Informatics, School of Pharmaceutical Sciences, Wakayama Medical University, 25-1 Nanabancho, Wakayama, Wakayama Prefecture 640-8156, Japan
| | - Harue Tada
- Department of Clinical Trial Science, Translational Research Center, Kyoto University Hospital, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Yu Hidaka
- Department of Clinical Trial Science, Translational Research Center, Kyoto University Hospital, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Satoshi Morita
- Department of Clinical Trial Science, Translational Research Center, Kyoto University Hospital, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Chihiro Funakoshi
- Department of Clinical Trial Science, Translational Research Center, Kyoto University Hospital, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Akemi Kinoshita
- Department of Clinical Trial Science, Translational Research Center, Kyoto University Hospital, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Mieko Watanabe
- Department of Clinical Trial Science, Translational Research Center, Kyoto University Hospital, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Itaru Tsuge
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Motoki Katsube
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Michiharu Sakamoto
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Tetsuji Yamaoka
- Department of Biomedical Engineering, National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe-Shinmachi, Suita, Osaka 564-8565, Japan
| | - Naoki Morimoto
- Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin, Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| |
Collapse
|
4
|
Hayashi K, Tanaka Y, Tsuda T, Nomura A, Fujino N, Furusho H, Sakai N, Iwata Y, Usui S, Sakata K, Kato T, Tada H, Kusayama T, Usuda K, Kawashiri MA, Passman RS, Wada T, Yamagishi M, Takamura M, Fujino N, Nohara A, Kawashiri MA, Hayashi K, Sakata K, Yoshimuta T, Konno T, Funada A, Tada H, Nakanishi C, Hodatsu A, Mori M, Tsuda T, Teramoto R, Nagata Y, Nomura A, Shimojima M, Yoshida S, Yoshida T, Hachiya S, Tamura Y, Kashihara Y, Kobayashi T, Shibayama J, Inaba S, Matsubara T, Yasuda T, Miwa K, Inoue M, Fujita T, Yakuta Y, Aburao T, Matsui T, Higashi K, Koga T, Hikishima K, Namura M, Horita Y, Ikeda M, Terai H, Gamou T, Tama N, Kimura R, Tsujimoto D, Nakahashi T, Ueda K, Ino H, Higashikata T, Kaneda T, Takata M, Yamamoto R, Yoshikawa T, Ohira M, Suematsu T, Tagawa S, Inoue T, Okada H, Kita Y, Fujita C, Ukawa N, Inoguchi Y, Ito Y, Araki T, Oe K, Minamoto M, Yokawa J, Tanaka Y, Mori K, Taguchi T, Kaku B, Katsuda S, Hirase H, Haraki T, Fujioka K, Terada K, Ichise T, Maekawa N, Higashi M, Okeie K, Kiyama M, Ota M, Todo Y, Aoyama T, Yamaguchi M, Noji Y, Mabuchi T, Yagi M, Niwa S, Takashima Y, Murai K, Nishikawa T, Mizuno S, Ohsato K, Misawa K, Kokado H, Michishita I, Iwaki T, Nozue T, Katoh H, Nakashima K, Ito S, Yamagishi M. Correction: Characterization of baseline clinical factors associated with incident worsening kidney function in patients with non-valvular atrial fibrillation: the Hokuriku-Plus AF Registry. Heart Vessels 2023; 38:412. [PMID: 36508013 DOI: 10.1007/s00380-022-02218-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Kenshi Hayashi
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.
| | - Yoshihiro Tanaka
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Center for Arrhythmia Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.,Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Toyonobu Tsuda
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Akihiro Nomura
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Noboru Fujino
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Hiroshi Furusho
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Department of Cardiology, Ishikawa Prefectural Central Hospital, 2-1, Kuratsuki-higashi, Kanazawa, Japan
| | - Norihiko Sakai
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Yasunori Iwata
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Soichiro Usui
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Kenji Sakata
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Takeshi Kato
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Hayato Tada
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Takashi Kusayama
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Keisuke Usuda
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Masa-Aki Kawashiri
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | - Rod S Passman
- Center for Arrhythmia Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.,Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Takashi Wada
- Department of Nephrology and Laboratory Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan
| | - Masakazu Yamagishi
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.,Osaka University of Human Sciences, Settsu, Osaka, Japan
| | - Masayuki Takamura
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, 13-1, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Watanabe K, Niikura N, Kikawa Y, Oba M, Kobayashi K, Tada H, Ozaki S, Toh U, Yamamoto Y, Tsuneizumi M, Okuno T, Iwakuma N, Takeshita T, Iwamoto T, Ishiguro H, Masuda N, Saji S. 228P Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Hamanishi J, Sumi E, Miyamoto T, Uozumi R, Yamanoi K, Tada H, Amino Y, Hidaka Y, Ukita M, Yamaguchi K, Asada R, Ajiro M, Sawada T, Hagiwara M, Mandai M. Safety of the cyclin dependent kinase 9 (CDK9) inhibitor FIT039 for cervical intraepithelial neoplasia (CIN) 1 or 2 in a phase I/II trial. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.3022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3022 Background: Human papillomaviruses (HPVs) infect uterine cervical epithelial cells, leading to cervical intraepithelial neoplasia (CIN) and cervical cancer. However, there is no treatment for HPV infection in the uterine cervix prior to vaccination. We recently reported that cyclin dependent kinase 9 (CDK9) plays a critical role in viral RNA transcription of DNA viruses such as HPVs in host cells, and that FIT-039, a specific inhibitor of CDK9, suppresses the proliferation of several DNA viruses. Here, we evaluated the safety and antiviral effect of a FIT039-releasing vaginal tablet (FIT039CT) for CIN1 or 2 (CIN1/2). Methods: A multi-institutional, single-blind, placebo-controlled randomized phase I/II clinical trial involving 2 cohorts was designed to evaluate the safety of transvaginal FIT039CT for CIN1/2 as follows:. In the first cohort, 8 healthy women were randomized into FIT039CT (50mg/day or 100mg/day) or control group. In the second cohort, 14 women with a primary diagnosis of CIN1/2 were randomized into either FIT039CT (100mg/day) or control group. The primary endpoints were adverse events and plasma concentrations of FIT039. Results: 22 patients (8 volunteers, 11 CIN1 and 3 CIN2) were enrolled. There were no serious adverse events. Adverse events considered related to treatment were mild (vaginal discharge Grade 1: FIT039CT 16/17 women [94%] vs placebo 2/6 [33%]) and self-limiting in both cohorts. No patient discontinued this study due to adverse events. Maximum concentration (C max) and terminal elimination half-life (t 1/2) of serum FIT039 concentrations after single transvaginal treatment of FIT039CT were similar between the two doses as follows; C max (mean ± standard deviation) was 4.5 ± 0.5 ng/mL (50mg/day) and 4.4 ±1.4 ng/mL (100mg/day) at 6-7 hours; mean t1/2 was 14.8 ± 2.1 hours (50mg/day) and 12.1 ± 2.6 hours (100mg/day) hours. Conclusions: This study demonstrated the safety and validity of transvaginal FIT039CT once a day and may contribute to the development of an antiviral agent that can cure CIN1/2, and supports the design of the ongoing phase 2 clinical study. Clinical trial information: jRCT2051180201.
Collapse
Affiliation(s)
- Junzo Hamanishi
- Kyoto University Graduate School of Medicine, Department of Gynecology and Obstetrics, Kyoto, Japan
| | | | - Taito Miyamoto
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Koji Yamanoi
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Harue Tada
- Translational Research Center,Kyoto University Hospital, Kyoto, Japan
| | | | - Yu Hidaka
- Kyoto University Hospital, Kyoto, Japan
| | | | | | | | - Masahiko Ajiro
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Teruo Sawada
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | - Masaki Mandai
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
7
|
Akamatsu S, Terada N, Takata R, Kinoshita H, Shimatani K, Momozawa Y, Yamamoto M, Tada H, Kawamorita N, Narita S, Kato T, Nitta M, Kandori S, Koike Y, Inazawa J, Kimura T, Kimura H, Kojima T, Terachi T, Sugimoto M, Habuchi T, Arai Y, Yamamoto S, Matsuda T, Obara W, Kamoto T, Inoue T, Nakagawa H, Ogawa O. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. JNCI Cancer Spectr 2022; 6:pkac001. [PMID: 35118230 PMCID: PMC8807580 DOI: 10.1093/jncics/pkac001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2021] [Revised: 09/10/2021] [Accepted: 09/30/2021] [Indexed: 11/25/2022] Open
Abstract
Background Multiple common variants and also rare variants in monogenic risk genes such as BRCA2 and HOXB13 have been reported to be associated with risk of prostate cancer (PCa); however, the clinical setting in which germline genetic testing could be used for PCa diagnosis remains obscure. Herein, we tested the clinical utility of a 16 common variant–based polygenic risk score (PRS) that has been developed previously for Japanese men and also evaluated the frequency of PCa-associated rare variants in a prospective cohort of Japanese men undergoing prostate biopsy. Methods A total of 1336 patients undergoing first prostate biopsy were included. PRS was calculated based on the genotype of 16 common variants, and sequencing of 8 prostate cancer–associated genes was performed by multiplex polymerase chain reaction based target sequencing. PRS was combined with clinical factors in logistic regression models to assess whether addition of PRS improves the prediction of biopsy positivity. Results The top PRS decile was associated with an odds ratio of 4.10 (95% confidence interval = 2.46 to 6.86) with reference to the patients at average risk, and the estimated lifetime absolute risk approached 20%. Among the patients with prostate specific antigen 2-10 ng/mL who had prebiopsy magnetic resonance imaging, high PRS had an equivalent impact on biopsy positivity as a positive magnetic resonance imaging finding. Rare variants were detected in 19 (2.37%) and 7 (1.31%) patients with positive and negative biopsies, respectively, with BRCA2 variants being the most prevalent. There was no association between PRS and high-risk rare variants. Conclusions Germline genetic testing could be clinically useful in both pre- and post-PSA screening settings.
Collapse
Affiliation(s)
- Shusuke Akamatsu
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
- RIKEN Center for Integrative Medical Sciences, Laboratory for Cancer Genomics, Kanagawa, Japan
| | - Naoki Terada
- Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
| | - Ryo Takata
- Department of Urology, School of Medicine, Iwate Medical University, Iwate, Japan
- RIKEN Center for Integrative Medical Sciences, Laboratory for Cancer Genomics, Kanagawa, Japan
| | - Hidefumi Kinoshita
- Department of Urology and Andrology, Kansai Medical University, Osaka, Japan
| | | | - Yukihide Momozawa
- Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan
| | - Michio Yamamoto
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
- Graduate School of Environmental and Life Science, Okayama University, Okayama, Japan
- RIKEN Center for Advanced Intelligence Project, Kanagawa, Japan
| | - Harue Tada
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Naoki Kawamorita
- Department of Urology, Tohoku University Graduate School of Medicine, Miyagi, Japan
| | - Shintaro Narita
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Takuma Kato
- Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan
| | - Masahiro Nitta
- Department of Urology, Tokai University School of Medicine, Kanagawa, Japan
| | - Shuya Kandori
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Yusuke Koike
- Department of Urology, Jikei University School of Medicine, Tokyo, Japan
| | - Johji Inazawa
- Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
| | - Takahiro Kimura
- Department of Urology, Jikei University School of Medicine, Tokyo, Japan
| | - Hiroko Kimura
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takahiro Kojima
- Department of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Toshiro Terachi
- Department of Urology, Tokai University School of Medicine, Kanagawa, Japan
| | - Mikio Sugimoto
- Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan
| | - Tomonori Habuchi
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Yoichi Arai
- Department of Urology, Tohoku University Graduate School of Medicine, Miyagi, Japan
| | - Shingo Yamamoto
- Department of Urology, Hyogo College of Medicine, Hyogo, Japan
| | - Tadashi Matsuda
- Department of Urology and Andrology, Kansai Medical University, Osaka, Japan
| | - Wataru Obara
- Department of Urology, School of Medicine, Iwate Medical University, Iwate, Japan
| | - Toshiyuki Kamoto
- Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
| | - Takahiro Inoue
- Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan
| | - Hidewaki Nakagawa
- RIKEN Center for Integrative Medical Sciences, Laboratory for Cancer Genomics, Kanagawa, Japan
| | - Osamu Ogawa
- Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | |
Collapse
|
8
|
Tada H, Hori M, Matsuki K, Ogura M, Nohara A, Kawashiri M, Hadara-Shiba M. Achilles tendon thickness assessed by X-ray predicting a pathogenic mutation in familial hypercholesterolemia gene. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The 2017 Japan Atherosclerosis Society (JAS) familial hypercholesterolemia (FH) criteria adopts a cut off value of ≥9 mm of Achilles tendon thickness (ATT) detected by X-ray as one of the three key items. This threshold was determined based on an old data assessing ATT of 36 non-FH individuals published in 1977. Although the specificity of this clinical criteria is extremely high due to a strict threshold, there are substantial number of patients with FH whose ATT <9 mm. We aimed to determine a cut off value of ATT detected by X-ray to differentiate FH and non-FH based on genetic diagnosis.
Methods
The individuals (male/female = 486/501) with full assessments of genetic analyses for FH-genes (LDLR, and PCSK9), serum lipids, and ATT detected by X-ray at Kanazawa University Hospital and National Cerebral and Cardiovascular Center Research Institute were included in this study. Receiver operating characteristic (ROC) analyses were performed to determine a better cut off point of ATT predicting a pathogenic mutation of FH.
Results
ROC analyses revealed the best cut off values of ATT as 7.6 mm for male, and 7.0 mm for female with the sensitivities and specificities of 0.83 and 0.83 for male and 0.86 and 0.85 for female, respectively. If the thresholds of ATT of 8.0/7.5 mm and 7.5/7.0 mm were applied to diagnose of male/female FH, the sensitivities/specificities predicting a pathogenic mutation of FH by the 2017 JAS FH clinical criteria would be 0.82/0.90 and 0.85/0.88, respectively.
Conclusions
These results suggest that the cut-off value of ATT detected by X-ray is obviously lower than 9.0 mm adopted by the 2017 JAS FH clinical criteria.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | - M Hori
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - K Matsuki
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - M Ogura
- National Cerebral & Cardiovascular Center, Suita, Japan
| | - A Nohara
- Ishikawa Prefectural Central Hospital, Kanazawa, Japan
| | | | | |
Collapse
|
9
|
Nojima Y, Mano T, Nishino M, Fuji K, Nakamura S, Tada H, Mizote I, Ashikaga T, Otsuji S, Takahashi A, Yonetsu T, Takahara M, Okayama K, Nanto S. Direct comparison of bioabsorbable and biodurable polymer everolimus-eluting stent in neointimal stent coverage and in-stent thrombus using high-resolution angioscope. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background/Introduction
Although second-generation drug eluting stent (DES) employing biodurable polymer drastically shortened the duration of dual antiplatelet therapy (DAPT), previous reports raised concerns that switching from DAPT to single antiplatelet therapy increased rates of subsequent stent thrombosis with time. Third-generation DES employing bioabsorbable polymer has been introduced so as not to hinder the healing process of the vessel wall, however, at present, both DES with bioabsorbable polymer and those with biodurable polymer are used in parallel. It means there is no conclusive evidence regarding pros and cons of these two types of polymers.
Purpose
This study aims to clarify how bioabsorbable polymer and biodurable polymer act on the human coronary artery by observing neointimal stent coverage (NIC) and in-stent thrombus by comparing the third-generation DES with bioabsorbable-polymer cobalt-platinum everolimus-eluting stent (BP CoPt-EES), and the second-generation DES with biodurable-polymer cobalt-chromium everolimus-eluting stent (DP CoCr-EES).
Methods
This is a multicenter observational study including 11 hospitals. We investigated 70 stents (BP CoPt-EES: 40, DP CoCr-EES: 30) of 60 cases, who underwent stent implantation followed by simultaneous observation by coronary angiography, IVUS and angioscopy within 6 to 12 months. For angioscopy, we used a recently available, high-resolution angioscope with a pixel count of 9,000 which realized both stent coverage analysis and planar thrombus detection precisely. Neointimal stent coverage was graded from G0: non coverage to G3: full coverage, and heterogeneity value of neointima was measured as the difference between maximum and minimum NIC grade.
Results
A strong relationship was observed between NIC grade and in-stent thrombus in all stents (p=0.0011), and between the heterogeneity value and stent thrombus (p=0.012). There was no statistical difference in NIC grade between BP CoPt-EES vs. DP CoCr-EES; grade 0: 0 (0.0%) vs. 2 (6.7%), grade 1: 13 (32.5%) vs. 11 (36.7%), grade 2: 6 (15.0%) vs. 6 (20.0%), grade 3: 21 (52.5%) vs. 11 (36.7%), p=0.17) and neither in the heterogeneity value of neointima (p=0.49). The ratio of stent thrombus did not reach statistical difference; 16 (40.0%) in BP CoPt-EES vs. 17 (56.7%) in DP CoCr-EES (p=0.23).
Conclusion
The existence of stent thrombus was associated with the neointimal stent coverage. There was no significant difference both in neointimal stent coverage and stent thrombus between bioabsorbable polymer cobalt-platinum EES and biodurable polymer cobalt-chromium EES after 6 to 12 months following stent deployment.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Boston Scientific JapanOvalis ltd
Collapse
Affiliation(s)
- Y Nojima
- Nishinomiya Municipal Central Hospital, Department of Cardiology, Nishinomiya, Japan
| | - T Mano
- Kansai Rosai Hospital, Cardiovascular Center, Amagasaki, Japan
| | - M Nishino
- Osaka Rosai Hospital, Division of Cardiology, Osaka, Japan
| | - K Fuji
- Sakurabashi-Watanabe Hospital, Osaka, Japan
| | - S Nakamura
- Kyoto-Katsura Hospital, Cardiovascular Center, Kyoto, Japan
| | - H Tada
- Fukui University Hospital, Department of Cardiovascular Medicine, Fukui, Japan
| | - I Mizote
- Osaka University Graduate School of Medicine, Department of Cardiovascular Medicine, Osaka, Japan
| | - T Ashikaga
- Musashino Red Cross Hospital, Tokyo, Japan
| | - S Otsuji
- Higashi Takarazuka Satoh Hospital, Takarazuka, Japan
| | | | - T Yonetsu
- Tokyo Medical and Dental University, Department of Cardiovascular Medicine, Tokyo, Japan
| | - M Takahara
- Osaka University Graduate School of Medicine, Department of Metabolic Medicine, Osaka, Japan
| | - K Okayama
- Osaka University Graduate School of Medicine, Department of Cardiovascular Medicine, Osaka, Japan
| | - S Nanto
- Nishinomiya Municipal Central Hospital, Department of Cardiology, Nishinomiya, Japan
| | | |
Collapse
|
10
|
Tada H, Okada H, Nohara A, Yamagishi M, Takamura M, Kawashiri M. Impact of cumulative exposure to LDL cholesterol on cardiovascular events in patients with familial hypercholesterolemia. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Aims
Recent studies suggest that cumulative exposure to LDL-cholesterol (LDL-C) leads to the development of atherosclerotic cardiovascular disease (ASCVD). However, few studies have investigated whether this link extends to individuals with familial hypercholesterolemia (FH), a relevant patient population. We aimed to determine whether cholesterol-year-score, an indicator of cumulative exposure to LDL-C, is associated with ASCVD events among Japanese patients with FH
Methods and results
We retrospectively investigated the health records of 1,050 patients with clinical FH diagnosis who were referred to our institute between April 1990 and March 2019. We used Cox proportional hazards models adjusted for established ASCVD risk factors to assess the association between cholesterol-year-score and major adverse cardiovascular events (MACEs), including death from any cause or hospitalization due to ASCVD events. Cholesterol-year-score was calculated as LDL-C max × [age at diagnosis / statin initiation] + LDL-C at inclusion × [age at inclusion − age at diagnosis / statin initiation]. The median follow-up period for MACE evaluation was 12.3 (interquartile range, 9.1–17.5) years, and 177 patients experienced MACEs during the observation period. Cholesterol-year-score was significantly associated with MACEs (hazard ratio [HR], 1.35; 95% confidence interval, 1.07–1.53; P=0.0034, per 1,000 mg-year/dL), independent of other traditional risk factors including age and LDL-C, based on cross-sectional assessment. Cholesterol-year-score improved the discrimination ability of other traditional risk factors for ASCVD events (C-index, 0.901 versus 0.889; P=0.00473).
Conclusion
Cumulative LDL-C exposure was strongly associated with MACEs in Japanese patients with FH, warranting early diagnosis and treatment initiation in these patients.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | - H Okada
- Kanazawa University, Kanazawa, Japan
| | - A Nohara
- Ishikawa Prefectural Central Hospital, Kanazawa, Japan
| | - M Yamagishi
- Osaka University of Human Sciences, Suita, Japan
| | | | | |
Collapse
|
11
|
Nakajima K, Nakata T, Doi T, Tada H, Saito S, Maruyama K. Creation of mortality risk calculator using a I-123 mIBG-based machine learning model: differential prediction of arrhythmic death and heart-failure death. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeab111.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Although I-123 meta-iodobenzylguanidine (mIBG) has been applied to patients with chronic heart failure (CHF), a diagnostic tool for differential prediction of fatal arrhythmic events (ArE) and heart-failure death (HFD) has been pursued.
Purpose
The aim of this study was to create a calculator of mortality risk for differentiating mode of cardiac death using a machine learning (ML) method, and to test the accuracy in a new cohort of patients with CHF.
Methods
A total of 529 patients with CHF was used as the training database for ML. The ArE group consisted of patients with arrhythmic death, sudden cardiac death and appropriate therapy by implantable cardioverter defibrillator. A heart-to-mediastinum ratio (H/M) standardized to the medium-energy collimator condition was calculated with a planar anterior mIBG scintigram. The best classifier models for predicting HFD and ArE were determined by four-fold cross validation. Input variables included age, sex, New York Heart Association (NYHA) functional class, left ventricular ejection fraction, ischemic etiology, mIBG H/M and washout rate, and b-type natriuretic peptide (BNP) or NT Pro BNP, estimated glomerular filtration rate, hemoglobin, and complications such as diabetes and hypertension. After creating the ML-based model, the constructed classifier functions for ArE, HFD, and survival were exported for subsequent use. A new cohort of patients (n = 312, age 67 ± 13 years, 2015 or later) was used to test the ML-based model.
Results
The training database included 141 events (27%) with ArE (7%) and HFD (20%). Receiver-operating characteristic analysis by four-fold validation showed area under the curve value of 0.90 for HFD and 0.73 for ArE. Among various ML methods, the logistic regression method demonstrated the most stable calculation of the probability of ArE followed by random forest and gradient boosted tree methods. Therefore, the logistic-regression method was used for calculating both HFD and ArE probabilities. In the test cohort, patients with a high HFD probability >8% resulted in 6.3-fold higher HFD than those with low probability (≤ 8%). Patients with high ArE probability >8% showed 2.5-fold higher ArE than those with low probability (≤ 8%).
Conclusion
The ML-based mortality risk calculator could be used for stratifying patients at high and low risks, which might be useful for estimating appropriate treatment strategy.
Collapse
Affiliation(s)
- K Nakajima
- Kanazawa University Graduate School of Medicine, Kanazawa, Japan
| | - T Nakata
- Hakodate Goryoukaku Hospital, Hakodate, Japan
| | - T Doi
- Teine Keijinkai Hospital, Sapporo, Japan
| | - H Tada
- Kanazawa University Hospital, Kanazawa, Japan
| | - S Saito
- Kanazawa University Hospital, Kanazawa, Japan
| | | |
Collapse
|
12
|
Kondo T, Banno H, Okunomiya T, Amino Y, Endo K, Nakakura A, Uozumi R, Kinoshita A, Tada H, Morita S, Ishikawa H, Shindo A, Yasuda K, Taruno Y, Maki T, Suehiro T, Mori K, Ikeda M, Fujita K, Izumi Y, Kanemaru K, Ishii K, Shigenobu K, Kutoku Y, Sunada Y, Kawakatsu S, Shiota S, Watanabe T, Uchikawa O, Takahashi R, Tomimoto H, Inoue H. Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. BMJ Open 2021; 11:e051343. [PMID: 34193504 PMCID: PMC8246358 DOI: 10.1136/bmjopen-2021-051343] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
INTRODUCTION Alzheimer's disease (AD) is one of the most common causes of dementia. Pathogenic variants in the presenilin 1 (PSEN1) gene are the most frequent cause of early-onset AD. Medications for patients with AD bearing PSEN1 mutation (PSEN1-AD) are limited to symptomatic therapies and no established radical treatments are available. Induced pluripotent stem cell (iPSC)-based drug repurposing identified bromocriptine as a therapeutic candidate for PSEN1-AD. In this study, we used an enrichment strategy with iPSCs to select the study population, and we will investigate the safety and efficacy of an orally administered dose of bromocriptine in patients with PSEN1-AD. METHODS AND ANALYSIS This is a multicentre, randomised, placebo-controlled trial. AD patients with PSEN1 mutations and a Mini Mental State Examination-Japanese score of ≤25 will be randomly assigned, at a 2:1 ratio, to the trial drug or placebo group (≥4 patients in TW-012R and ≥2 patients in placebo). This clinical trial consists of a screening period, double-blind phase (9 months) and extension phase (3 months). The double-blind phase for evaluating the efficacy and safety is composed of the low-dose maintenance period (10 mg/day), high-dose maintenance period (22.5 mg/day) and tapering period of the trial drug. Additionally, there is an open-labelled active drug extension period for evaluating long-term safety. Primary outcomes are safety and efficacy in cognitive and psychological function. Also, exploratory investigations for the efficacy of bromocriptine by neurological scores and biomarkers will be conducted. ETHICS AND DISSEMINATION The proposed trial is conducted according to the Declaration of Helsinki, and was approved by the Institutional Review Board (K070). The study results are expected to be disseminated at international or national conferences and published in international journals following the peer-review process. TRIAL REGISTRATION NUMBER jRCT2041200008, NCT04413344.
Collapse
Affiliation(s)
- Takayuki Kondo
- Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
| | - Haruhiko Banno
- Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Taro Okunomiya
- Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Yoko Amino
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Kayoko Endo
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Akiyoshi Nakakura
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Ryuji Uozumi
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Akemi Kinoshita
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Harue Tada
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| | - Satoshi Morita
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Hidehiro Ishikawa
- Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Akihiro Shindo
- Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Ken Yasuda
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Yosuke Taruno
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takakuni Maki
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takashi Suehiro
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan
| | - Kohji Mori
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan
| | - Manabu Ikeda
- Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan
| | - Koji Fujita
- Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Yuishin Izumi
- Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
| | - Kazutomi Kanemaru
- Department of Stroke, Tokyo Metropolitan Geriatric Medical Center, Tokyo, Japan
| | - Kenji Ishii
- Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
| | | | - Yumiko Kutoku
- Department of Neurology, Kawasaki Medical School, Kurashiki, Japan
| | - Yoshihide Sunada
- Department of Neurology, Kawasaki Medical School, Kurashiki, Japan
| | - Shinobu Kawakatsu
- Department of Neuropsychiatry, Fukushima Medical University Aizu Medical Center, Aizu, Japan
| | | | | | | | - Ryosuke Takahashi
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Hidekazu Tomimoto
- Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan
| | - Haruhisa Inoue
- Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
13
|
Tada H, Nohara A, Kawashiri MA. Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Tada H, Okada H, Nomura A, Nohara A, Yamagishi M, Takamura M, Kawashiri M. Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2983] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Early diagnosis and timely treatment for the patients with familial hypercholesterolemia (FH) can substantially lower the risk of atherosclerotic cardiovascular disease (ASCVD). In this sense, cascade screening could be one of the most useful options. However, few data exist regarding the impact of cascade screening for FH on the reduction of risk of ASCVD events.
Objectives
We aimed to evaluate the prognostic impact of cascade screening for FH.
Methods
We retrospectively investigated the health records of 1,050 patients with clinically diagnosed FH, including probands and their relatives who were cascade-screened. We used Cox models that were adjusted for established ASCVD risk factors to assess the association between cascade screening and major adverse cardiovascular events (MACE). The median period of follow-up was 12.3 years (interquartile range [IQR] = 9.1–17.5 years), and MACE included death from any causes or hospitalization due to ASCVD events.
Results
During the observation period, 246 participants experienced MACE. The mean age of patients identified through cascade screening was 18-years younger than that of the probands (38.7 yr vs. 57.0 yr, P<0.001), with a lower proportion of ASCVD risk factors. Interestingly, patients identified through cascade screening under milder lipid-lowering therapies were at reduced risk for MACE (hazard ratio [HR] = 0.36; 95% CI = 0.22 to 0.60; P<0.001) when compared with the probands, even after adjusting for those known risk factors.
Conclusions
The identification of patients with FH via cascade screening appeared to result in better prognoses.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Scientific research grants from the Ministry of Education, Science and Culture of Japan (no. 16K19394, 18K08064, and 19K08575)
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | - H Okada
- Kanazawa University, Kanazawa, Japan
| | - A Nomura
- Kanazawa University, Kanazawa, Japan
| | - A Nohara
- Kanazawa University, Kanazawa, Japan
| | | | | | | |
Collapse
|
15
|
Usuda K, Kato T, Tada H, Tsuda T, Takeuchi K, Niwa S, Usui S, Sakata K, Hayashi K, Furusho H, Kawashiri M, Takamura M, Nagashima K, Okumura Y. Recurrence of atrial fibrillation after catheter ablation is associated with major adverse cardiac and cerebrovascular events: insights from AF frontier ablation registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Recent observational studies have suggested that catheter ablation for atrial fibrillation (AF) is significantly associated with reduced risk for stroke, cardiovascular events and all-cause death. However, little is known whether late recurrence of AF after catheter ablation is associated with worse clinical outcomes.
Purpose
We aimed to clarify whether late recurrence of AF after catheter ablation is associated with major adverse cardiac and cerebrovascular events (MACCE).
Methods
We retrospectively investigated 2,737 participants (74.4% men, mean age 63.4±10.3 years, 62.7% paroxysmal AF) who received first catheter ablation for AF and completed follow-up more than 3 months after the procedure from AF Frontier Ablation Registry, a multicenter cohort study in Japan. We evaluated an association between late recurrence of AF after catheter ablation and first MACCE in cox-regression hazard models adjusted for known risk factors. MACCE were defined as stroke/transient ischemic attack (TIA), cardiovascular events or all-cause death. Late recurrence was defined as AF relapse more than 3 months after the procedure.
Results
During a mean follow-up period of 25.2 months, 2,070 patients (75.6%) were free from AF after catheter ablation and 122 patients (4.5%) had MACCE (ischemic stroke 18 [14.8%], hemorrhagic stroke 16 [13.1%], TIA 7 [5.7%], hospitalization for heart failure 19 [15.6%], acute coronary syndrome 19 [15.6%], hospitalization for other cardiovascular events 24 [20%] and all-cause death 19 [15.6%]). The MACCE occurred significantly more frequently in the recurrence group than in non-recurrence group (7.5% vs. 3.5%; hazard ratio [HR] 1.85; 95% confidence interval [CI] 1.28–2.65; P=0.001) (Figure). Multivariate analysis revealed that baseline age (HR 1.05; 95% CI 1.03–1.08; P<0.001), heart failure (HR 1.76; 95% CI 1.17–2.66; P=0.007), old myocardial infarction (HR 4.49; 95% CI 2.59–7.81; P<0.001), non-ischemic cardiomyopathy (HR 2.56; 95% CI 1.47–4.46; P=0.001), left atrial diameter (HR 1.22 per 5-mm increase; 95% CI, 1.06–1.41; P=0.006) and recurrence of AF (HR 1.69; 95% CI 1.17–2.44; P=0.005) were independently associated with the incidence of MACCE after catheter ablation.
Conclusion
In the Japanese multicenter cohort of AF ablation, late recurrence of AF was independently associated with increased MACCE, suggesting the significance of sinus rhythm maintenance by catheter ablation.
Kaplan-Meier curves for MACCE
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Usuda
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - T Kato
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - H Tada
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - T Tsuda
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - K Takeuchi
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - S Niwa
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - S Usui
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - K Sakata
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - K Hayashi
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - H Furusho
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - M Kawashiri
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - M Takamura
- Kanazawa University Hospital, Department of Cardiology, Kanazawa, Japan
| | - K Nagashima
- Nihon University Hospital, Department of Cardiovascular Medicine, Tokyo, Japan
| | - Y Okumura
- Nihon University Hospital, Department of Cardiovascular Medicine, Tokyo, Japan
| |
Collapse
|
16
|
Kato T, Usuda K, Tada H, Tsuda T, Takeuchi K, Niwa S, Hayashi K, Furusho H, Takamura M, Nagashima K, Okumura Y. B-Type natriuretic peptide predicts major adverse cardiac and cerebrovascular events after catheter ablation of atrial fibrillation: insights from AF frontier ablation registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
High plasma B-Type natriuretic peptide (BNP) level is associated with cardiac events or stroke in patients with atrial fibrillation (AF). However, it is still unknown whether BNP predicts worse clinical outcomes after catheter ablation ofAF.
Purpose
We aimed to see if plasma BNP level is associated with major adverse cardiac and cerebrovascular events (MACCE) after catheter ablation of AF.
Methods
We retrospectively analyzed 1,853 participants (73.1% men, mean age 63.3±10.3 years, 60.7% paroxysmal AF) who received first catheter ablation of AF with pre-ablation plasma BNP level measurement and completed follow-up more than 3 months after the procedure from AF Frontier Ablation Registry, a multicenter cohort study in Japan. We evaluated an association between plasma BNP level before catheter ablation and first MACCE in cox-regression hazard models adjusted for known risk factors. MACCE were defined as stroke/transient ischemic attack (TIA), cardiovascular events or all-cause death.
Results
The mean plasma BNP level was 120.2±3.7 pg/mL. During a mean follow-up period of 21.9 months, 57 patients (3.1%) suffered MACCE (ischemic stroke 8 [14.0%], hemorrhagic stroke 5 [8.8%], TIA 5 [8.8%], hospitalization for heart failure 11 [19.2%], acute coronary syndrome 9 [15.8%], hospitalization for other cardiovascular events 8 [14.0%] and all-cause death 11 [19.2%]). Plasma BNP level of patients with MACCE were significantly higher than those without MACCE (291.7±47.0 vs 114.7±3.42 pg/mL, P<0.001). Multivariate analysis revealed that plasma BNP level (hazard ratio [HR] per 10 pg/mL increase 1.014; 95% confidence interval [CI] 1.005–1.023; P=0.001), baseline age (HR 1.052; 95% CI 1.022–1.084; P=0.001), heart failure (HR 2.698; 95% CI 1.512–4.815; P=0.001), old myocardial infarction (HR 3.593; 95% CI 1.675–7.708; P=0.001) and non-ischemic cardiomyopathy (HR 2.676; 95% CI 1.337 - 5.355; P=0.005) were independently associated with MACCE. At receiver-operating characteristic curve analysis, plasma BNP level before catheter ablation ≥162.7 pg/mL was the best threshold to predict MACCE (area under the curve: 0.71). Kaplan-Meier curve analysis (Figure) showed that the cumulative incidence of MACCE was significantly higher in patients with a BNP ≥162.7 pg/mL than in those with a BNP below 162.7 pg/mL (HR 4.85; 95% CI 2.86–8.21; P<0.001).
Conclusions
Elevation of plasma BNP level was independently related to the increased risk of MACCE after catheter ablation ofAF.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Bristol-Meiers Squibb
Collapse
Affiliation(s)
- T Kato
- Kanazawa University, Kanazawa, Japan
| | - K Usuda
- Kanazawa University, Kanazawa, Japan
| | - H Tada
- Kanazawa University, Kanazawa, Japan
| | - T Tsuda
- Kanazawa University, Kanazawa, Japan
| | | | - S Niwa
- Kanazawa University, Kanazawa, Japan
| | - K Hayashi
- Kanazawa University, Kanazawa, Japan
| | - H Furusho
- Kanazawa University, Kanazawa, Japan
| | | | | | | |
Collapse
|
17
|
Sato Y, Uzui H, Aiki Y, Aoyama D, Yamaguchi J, Nodera M, Shiomi Y, Hasegawa K, Ikeda H, Tama N, Fukuoka Y, Morishita T, Ishida K, Miyazaki S, Tada H. Effects of PCSK9 inhibitor on adverse limb outcomes in patients with critical limb ischemia. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2375] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9-I), evolocumab, reduced the risk of cardiovascular event in patients with peripheral artery disease in FOURIER trial. However, the effects of evolocumab on favorable limb outcomes in patients with critical limb ischemia (CLI) is still unclear.
Purpose
The aim of this study was to evaluate the impacts of evolocumab on favorable limb outcomes and lipid profile in patients with CLI.
Methods
This was a single center, prospective observational study. A total of 39 patients with CLI were enrolled between November 2016 to May 2019. The subjects were divided into 2 groups based on evolocumab administration: evolocumab-treated group: E group (mean 69.4±11.7 years, n=14) and evolocumab non-treated group: Non-E group (mean 74.0±8.8 years, n=25). Baseline characteristics were assessed at admission. Lipid profile was evaluated at admission, 1, 3, 6, 12 and 18 months. The primary outcome was defined 18-month amputation-free survival (AFS). The secondary outcomes were defined 18-month overall survival (OS) and wound-free limb salvage. Mean follow-up period was 18±11 months.
Results
The patients in E group had greater reduction in levels of LDL cholesterol and non-HDL cholesterol than those in Non-E group over time. The reduction in MDA-LDL level was maintained at 1, 3, 6, 12 months, respectively. The 18-month AFS rate in the E-group was significantly higher than those in the Non-E group (log-rank p=0.02). The patients receiving evolocumab had a lower hazard regarding AFS (hazard ratio, 0.12; 95% confidence interval, 0.02–0.94; P=0.043) and a higher proportion of wound-free limb salvage at 12 months (E group [92%] vs Non-E group [57%], P=0.034) and 18 months (92% vs 52%, P=0.03). Otherwise, evolocumab administration was not associated with 18-month OS (log-rank p=0.053).
Conclusions
Evolocumab administration may be associated with the favorable outcome of 18-month AFS in the patients with CLI. Additionally, long-term administration of evolocumab over 12 months may improve wound-free limb salvage.
Effects of evolocumab on limb outcomes
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- Y Sato
- University of Fukui, Fukui, Japan
| | - H Uzui
- University of Fukui, Fukui, Japan
| | - Y Aiki
- University of Fukui, Fukui, Japan
| | - D Aoyama
- University of Fukui, Fukui, Japan
| | | | - M Nodera
- University of Fukui, Fukui, Japan
| | - Y Shiomi
- University of Fukui, Fukui, Japan
| | | | - H Ikeda
- University of Fukui, Fukui, Japan
| | - N Tama
- University of Fukui, Fukui, Japan
| | | | | | - K Ishida
- University of Fukui, Fukui, Japan
| | | | - H Tada
- University of Fukui, Fukui, Japan
| |
Collapse
|
18
|
Togami K, Yamaguchi K, Tada H, Chono S. Assessment of transporter-mediated efflux of nintedanib using in vitro cell line models of idiopathic pulmonary fibrosis. Pharmazie 2020; 75:371-374. [PMID: 32758335 DOI: 10.1691/ph.2020.0048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Objective: We aimed to investigate the involvement of efflux transporters, including multidrug resistant protein 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), MRP2, and breast cancer resistance protein (BCRP), in the intracellular accumulation of the antifibrotic agent nintedanib in fibrotic lung cells. Methods: We used transforming growth factor-β1 (TGF-β1)-treated human lung fibroblasts (WI-38) and alveolar epithelial cells (A549) as in vitro models. The expression and activities of efflux transporters in TGF-β1-treated WI-38 and A549 cells were evaluated using immunoblotting and flow cytometry. Cells were treated with nintedanib and then incubated with inhibitors of these transporters. The intracellular concentration of nintedanib was determined. Results: MDR1, MRP1, MRP2, and BCRP were found to be expressed in WI-38 and A549 cells with or without TGF-β1 stimulation, with the exception of MRP2 in WI-38 cells. The efflux activities of these transporters were observed in these cells. MDR1 inhibitors significantly increased the intracellular accumulation of nintedanib, whereas MRP inhibitors did not show an effect. The BCRP inhibitor significantly increased the transporter activity in A549 cells but not in WI-38 cells. Conclusion: This study suggests that the efflux via MDR1 and BCRP is involved in the intracellular accumulation of nintedanib in fibrotic lung cells.
Collapse
Affiliation(s)
- K Togami
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science; Creation Research Institute of Life Science in KITA-no-DAICHI, Sapporo, Japan;,
| | - K Yamaguchi
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan
| | - H Tada
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan
| | - S Chono
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science; Creation Research Institute of Life Science in KITA-no-DAICHI, Sapporo, Japan
| |
Collapse
|
19
|
Ikeda HO, Muraoka Y, Hata M, Sumi E, Ikeda T, Nakagawa T, Abe H, Tada H, Morita S, Kakizuka A, Yoshimura N, Tsujikawa A. Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial. PLoS One 2020; 15:e0229068. [PMID: 32053676 PMCID: PMC7018138 DOI: 10.1371/journal.pone.0229068] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Accepted: 01/28/2020] [Indexed: 11/30/2022] Open
Abstract
Kyoto University Substance (KUS) 121, an ATPase inhibitor of valosin-containing protein, is a novel neuroprotectant. We tested the safety and effectiveness of KUS121 in patients with acute central retinal artery occlusion (CRAO). We conducted an investigator-initiated, first-in-humans, phase 1/2 clinical trial. Nine patients with non-arteritic CRAO symptoms lasting for 4–48 h were enrolled. These patients received daily intravitreal injections of KUS121 for 3 days: 25 μg (low-dose) in the first three patients and 50 μg (high-dose) in the next six patients. The primary endpoint was the safety of the drug. As a secondary endpoint, pharmacokinetics was evaluated. Other key secondary endpoints were changes in best-corrected visual acuity (BCVA), measured using the Early Treatment Diabetic Retinopathy Study chart, visual field scores, and retinal sensitivities between baseline and week 12; and decimal BCVA at week 12. Administration of KUS121 did not result in serious adverse events. All nine patients (100%) showed significant improvement of BCVA. Average readable letter counts, visual field scores, and retinal sensitivities also improved. Decimal BCVA at week 12 was better than 0.1 in four patients (44%) and equal to or better than 0.05 in seven patients (78%). This first-in-humans clinical trial provides support for the safety and efficacy of intravitreal KUS121 injection. To substantiate the safety and effectiveness for patients with acute CRAO, further larger scale clinical studies will be needed.
Collapse
Affiliation(s)
- Hanako Ohashi Ikeda
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Yuki Muraoka
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Masayuki Hata
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Eriko Sumi
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Takafumi Ikeda
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Takayuki Nakagawa
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Hiroyasu Abe
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Harue Tada
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Satoshi Morita
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Akira Kakizuka
- Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies & Solution Oriented Research for Science and Technology, Kyoto, Japan
| | - Nagahisa Yoshimura
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Akitaka Tsujikawa
- Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
20
|
Tada H, Nohara NA, Kawashiri MK, Takamura MT. P6201Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Use of ezetimibe on top of statin therapy has been shown to be effective to reduce LDL cholesterol level in hypercholesterolemic patients. However, little is known regarding the individual variety of the effectiveness of ezetimibe. We hypothesized that hypercholesterolemic patients with a mutation in ABCG5 or ABCG8 gene exhibit better response to ezetimibe that those without, based on the fact that ezetimibe is hyper-effective for in patients with sitosterolemia caused by ABCG5 or ABCG8 genetic mutations.
Methods
Electronical medical record were reviewed in a total of 321 hypercholesterolemic patients (baseline LDL cholesterol = 192±46 mg/dl) prescribed ezetimibe 10 mg daily on top of atorvastatin 10mg daily who had undergone genetic analysis of ABCG5 or ABCG8 gene in our institute since 2006 to 2017. Pathogenicity of the variants were determined using standard variant filtering schema, including minor allele frequency, in silico annotation tools. Patients were divided into 2 groups based on the presence of ABCG5 or ABCG8 mutation. We compared the percent reduction of LDL cholesterol as well as the achieved LDL cholesterol levels between these 2 groups.
Results
We found 26 (8%) individuals who exhibit deleterious mutations in ABCG5 or ABCG8 gene. Baseline characteristics under the atorvastatin 10mg therapy were comparable in age, gender, and LDL cholesterol level between 2 groups. Under these conditions, percent reduction of LDL cholesterol in mutation positive group was significantly larger than that of mutation negative group (28±16% vs. 39±21%, p<0.05). As a result, the achieved LDL cholesterol level in mutation positive group was significantly lower than that of mutation negative group (87±29 mg/dl vs. 72±26% mg/dl, p<0.05).
Conclusion
These results suggest that ezetimibe-atorvastatin combination therapy might be more beneficial in hypercholesterolemic patients with a mutation in ABCG5 or ABCG8 gene.
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | | | | | | |
Collapse
|
21
|
Yoshida S, Nomura A, Tada H, Sakata K, Nakanishi C, Fujino N, Hosomichi K, Tajima A, Takamura M. 3073Leveraging transcriptome sequencing for detecting novel disease-related pathways using human cardiac sarcoidosis myocardium biopsies. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
Cardiac sarcoidosis (CS) is one of the main causes of poor outcomes in patients with sarcoidosis, a systemic granulomatous disorder of complex etiology including a genetically susceptible host and specific exposure to disease-triggering antigens. Recently, transcriptome analysis using sarcoidosis peripheral monocytes was reported to be useful for exploring genetic susceptibility and novel disease-causing pathways. However, transcriptome sequencing has not been used to explore disease-related genes and pathways directly using human CS myocardial biopsies.
Purpose
This study aimed to identify transcriptome profiles and novel disease-related pathways of CS by comparing human CS myocardial biopsies with control samples using ribonucleic acid (RNA) sequencing (RNA-Seq).
Methods
We assessed 30 patients with suspected myocardial disorders who underwent transcatheter endomyocardial biopsies at our University Hospital, Japan. Of those, 7 were clinically diagnosed with CS, 9 with hypertrophic cardiomyopathy (HCM), and 14 with dilated cardiomyopathy (DCM). Messenger RNAs were extracted from cardiac muscle biopsies using the Ovation SoLo RNA-Seq System (NuGEN Technologies), according to the manufacturer's instructions. Sequencing was performed with coverage of approximately 20 million reads per sample using Illumina HiSeq 2000. Sequencing reads were mapped using the STAR 2-pass method with GRCh37 as the reference. The DESeq2 R package (version 3.8) was used for further analyses. Principal component analysis (PCA) on gene expression was conducted for detecting outliers such as non-muscular samples. Differential gene expression analysis was performed between the 7 patients with CS and 23 patients with cardiomyopathy (HCM and DCM, non-CS). Gene Ontology (GO) enrichment analysis was conducted to estimate possible disease-related pathways.
Results
We successfully sequenced 60 myocardial biopsy samples (original and biological duplicates) from 30 CS patients. Of these, 2 outlier samples shown by the PCA plot were removed, and 58 were used for further analyses. We found 243 genes that were differentially expressed between CS patients and non-CS patients. Top-rated genes were RP11–366M4.8, RELN, S100A6, WASF3and UCHL1. Pathway analysis using GO demonstrated enrichment oflymphocyte activation (P=4.8x10–16), organelle fission (P=6.1x10–14), the M phase of the mitotic cell cycle (P=2.2x10–13), nuclear division (P=2.4x10–13), mitosis (P=2.4x10–13) and T-cell activation pathways (P=1.2x10–12).
Conclusions
Our differential gene expression and pathway analysis results using human CS myocardial biopsies suggested that lymphocyte activation, specifically the T-cell activation pathway, is linked to CS pathogenesis. Further studies are needed to decipher the role of specific genes related to genetic susceptibility and/or pathways associated with CS occurrence.
Collapse
Affiliation(s)
- S Yoshida
- Kanazawa University Graduate School of Medicine, Department of Cardiology, Kanazawa, Japan
| | - A Nomura
- Kanazawa University Graduate School of Medicine, Department of Cardiology, Kanazawa, Japan
| | - H Tada
- Kanazawa University Graduate School of Medicine, Department of Cardiology, Kanazawa, Japan
| | - K Sakata
- Kanazawa University Graduate School of Medicine, Department of Cardiology, Kanazawa, Japan
| | - C Nakanishi
- Kanazawa University Graduate School of Medicine, Department of Cardiology, Kanazawa, Japan
| | - N Fujino
- Kanazawa University Graduate School of Medicine, Department of Cardiology, Kanazawa, Japan
| | - K Hosomichi
- Kanazawa University Graduate School of Advance Preventive Medical Sciences, Department of Bioinformatics and Genomics, Kanazawa, Japan
| | - A Tajima
- Kanazawa University Graduate School of Advance Preventive Medical Sciences, Department of Bioinformatics and Genomics, Kanazawa, Japan
| | - M Takamura
- Kanazawa University Graduate School of Medicine, Department of Cardiology, Kanazawa, Japan
| |
Collapse
|
22
|
Kojima N, Tada H, Kawashiri M, Takamura M. P6202Serum sitosterol levels and ABCG5 and ABCG8 genetic mutations among Japanese dyslipidemic subjects. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Sitosterolemia, which is caused by ABCG5 or ABCG8 genetic mutations, is involved with marked increased concentrations of cholesterol as well as non-cholesterol plant sterols including sitosterol. Assessments of serum sitosterol level is critical to discriminate this disease from familial hypercholesterolemia (FH), which exhibits similar phenotypes except for elevated sitosterol levels. However, no prior data exist regarding the optimal cutoff value of serum sitosterol predicting the presence of sitosterolemia with double pathogenic mutations in ABCG5 or ABCG8 genes.
Methods
We retrospectively investigated consecutive 253 Japanese dyslipidemic subjects (mean age = 47.02 yr, male = 48.6%) with the assessments of serum sitosterol level as well as the presence of ABCG5 or ABCG8 genetic mutations in our institute since 2009 to 2018. Exome lesions of those 2 genes were sequenced, and pathogenicity of the identified genetic variants were determined using standard variant filtering schema, including minor allele frequency, in silico annotation tools. We divided the subjects into 3 groups based on the number of pathogenic mutations in ABCG5 or ABCG8 genes. We compared serum lipid values, including LDL cholesterol as well as serum sitosterol among those groups, and tried to determine the optimal cutoff value discriminating patients of sitosterolemia with double mutations from others.
Results
We identified 11 individuals with sitosterolemia with double mutations, 27 individuals with a single mutation, and 215 individuals without any mutations. Distribution of serum sitosterol exhibited skewed to the right (Figure). There was no significant correlation between serum sitosterol and other lipids, including LDL cholesterol. As expected, serum sitosterol level of patients with sitosterolemia exhibited significantly higher than those of any other groups (52.0 vs. 7.9 μg/ml, p=2.22×10–6, 52.0 vs. 2.8 μg/ml, p=2.275×10–8). 15 μg/ml was the optimal cut-off value, the sensitivity and specificity of which were 100%, and 99.6%, respectively.
Histgram of serum sitosterol
Conclusion
We suggest the cutoff sitosterol value of 15 μg/ml predicting the presence of sitosterolemia with double pathogenic ABCG5 or ABCG8 genetic mutations.
Collapse
Affiliation(s)
- N Kojima
- Kanazawa University, Kanazawa, Japan
| | - H Tada
- Kanazawa University Hospital, Kanazawa, Japan
| | | | | |
Collapse
|
23
|
Hasegawa K, Miyazaki S, Kaseno K, Hisazaki K, Ito H, Uzui H, Tada H. P5641Impact of lethal arrhythmias on medical castration in patients with prostate cancer. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Prostate cancer is the most common non-cutaneous malignancy in men and has been steadily rising in an aging society. Medical castration had been widely applied as a treatment for prostate cancer. Sex steroid hormones regulate cardiac ion channels. However, the proarrhythmic properties of medical castration have not been reported.
Methods
This prospective observational study consisted of 149 patients (75±6 years) who underwent hormonal therapy using gonadotropin-releasing hormone with or without anti-androgen for prostate cancer. The changes of electrocardiogram (ECG) findings during the therapy and the associations of ECG findings with lethal arrhythmias were studied.
Results
QT (394±32 to 406±39 ms, p<0.001) and QTc intervals (416±27 to 439±31 ms, p<0.001) significantly prolonged during the therapy as compared to baseline. Heart rate significantly increased during the therapy as compared to baseline (68±11 to 71±14 / min, p=0.006). PQ interval and QRS duration were similar before and during the therapy. During the hormonal therapy, 2 patients (1.3%) presented with torsades de pointes and ventricular fibrillation. The first patient was 71 year-old and the second patient was 70 year-old. The period of the therapy was 6 and 45 months, respectively. Both patients had no structural heart disease. The magnitude of QTc interval change during the therapy as compared to baseline (Δ QTc interval) was significantly greater in patients with VF than those without (p<0.001), however the magnitude of Δ heart rate, Δ PQ interval, and Δ QRS duration were similar between the 2 groups.
Conclusions
Medical castration significantly prolonged QT/QTc interval and could be a trigger of lethal arrhythmias in patients with prostate cancer.
Collapse
Affiliation(s)
- K Hasegawa
- University of Fukui, Cardiovascular Medicine, Fukui, Japan
| | - S Miyazaki
- University of Fukui, Cardiovascular Medicine, Fukui, Japan
| | - K Kaseno
- University of Fukui, Cardiovascular Medicine, Fukui, Japan
| | - K Hisazaki
- University of Fukui, Cardiovascular Medicine, Fukui, Japan
| | - H Ito
- University of Fukui, Department of Urology, Fukui, Japan
| | - H Uzui
- University of Fukui, Department of Urology, Fukui, Japan
| | - H Tada
- University of Fukui, Department of Urology, Fukui, Japan
| |
Collapse
|
24
|
Tada H, Okada H, Nomura A, Nohara A, Kawashiri M, Takamura M. P649Validation of clinical diagnostic criteria of familial hypercholesterolemia in Japan: evidence from a comprehensive genetic analysis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Although awareness of familial hypercholesterolemia (FH) is increasing, this common, potentially fatal, treatable condition remains underdiagnosed. Japanese clinical diagnostic criteria of FH include LDL cholesterol level ≥180 mg/dl, Achilles tendon thickness (ATT) ≥9.0 mm, and family history of FH or premature coronary disease. Despite FH being a genetic disorder, genetic testing is rarely used, few data exist regarding the validation of those criteria, especially, by studies using comprehensive genetic analyses.
Methods
This study included 680 subjects (344 men, mean LDL cholesterol = 175 mg/dl) who underwent the full assessments for FH, including LDL cholesterol measurement, Achilles tendon X-ray, investigations for family history, and comprehensive genetic analyses on FH-associated genes (LDL receptor, PCSK9, APOB, and LDLRAP1) in our University Hospital since 2006 to 2018. The area under curve (AUCs) of receiver-operating characteristic (ROC) curve analyses predicting FH-mutation positive were compared among those determined by each component.
Results
ROC analyses revealed the optimal cutoff LDL cholesterol value for predicting the presence of FH-mutation was 181 mg/dl, and that of ATT was ≥7.0 mm. AUCs of each component (ATT, LDL cholesterol, and family history) were 0.827, 0.889, and 0.906, respectively, and the combination of all components increased it to 0.975. When adopting ATT ≥7.0 mm as one of the clinical diagnostic criteria, 13 individuals (2%) were newly classified as true-FH, whereas, 27 (4%) individuals were newly misclassified as FH.
Conclusion
The current Japanese clinical diagnostic criteria of FH were pretty well validated in our independent cohort. However, the threshold of ATT could be lowered to 7.0 mm to raise the sensitivity of its criteria.
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | - H Okada
- Kanazawa University, Kanazawa, Japan
| | - A Nomura
- Kanazawa University, Kanazawa, Japan
| | - A Nohara
- Kanazawa University, Kanazawa, Japan
| | | | | |
Collapse
|
25
|
Aoyama D, Morishita T, Yamaguchi J, Shiomi Y, Ikeda H, Tama N, Fukuoka Y, Hasegawa K, Kaseno K, Ishida K, Miyazaki S, Uzui H, Tada H. P6339Sequential organ failure assessment score on admission predicts long-time mortality of the patients with acute heart failure. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Despite the remarkable advances in the treatment options of acute heart failure (HF), prognosis assessment remains an ongoing challenge. Previous studies revealed only a moderate accuracy of models predicting mortality. Sequential Organ Failure Assessment (SOFA) Score are widely used in the intensive care unit (ICU) to predict outcome and predicted higher long-time mortality in unselected patients in cardiac ICU. In addition, the American Heart Association Get With the Guidelines–Heart Failure (GWTG-HF) risk score allows for risk stratification of 30-day outcome for patients hospitalized with HF. The purpose of this study was to evaluate whether SOFA score on admission is useful for long-time mortality prediction in acute HF patients and also to assess the discriminative performance as compared with GWTG-HF risk score.
Methods
This was a single-centre, retrospective cohort study. Between January 2007 and December 2016, we screened eligible 661 consecutive patients with acute HF administered at our hospital. SOFA score on admission of 294 patients was able to calculate retrospectively. We enrolled 269 patients who could complete follow up evaluation for more than 1 year. Endpoint was all-cause mortality after admission. Additive information of SOFA score was evaluated by area under the curve (AUC), net reclassification improvement (NRI), integrated discrimination improvement (IDI) and decision curve analysis (DCA).
Results
The 269 patients were included in this study (78.5±10.9 years; 136 men; left ventricular ejection fraction [EF], 49.8±16.6%) during a mean follow-up of 32.1±22.3 months. Patients with all-cause death had higher SOFA score (4.2±2.3 versus 2.8±1.8, p<0.001; AUC, 0.689) and GWTG-HF risk score (44.0±7.6 versus 38.1±7.9, P<0.001, AUC, 0.692).
Kaplan-Meier survival analysis demonstrated higher SOFA scores (P<0.001) and GWTG-HF risk scores (P<0.001) appears to be related to increase probabilities of all cause death. A multivariate Cox proportional hazard model were made with adjustment for SOFA score, GWTG-HF risk score, age, gender and ejection fraction. As a result, SOFA score (hazard ratio [HR] 1.227; 95% confidence interval [CI], 1.130 to 1.326; P<0.001), GWTG-HF (HR, 1.054; 95% CI, 1.029 to 1.078; P<0.001) and age (HR, 1.069; 95% CI 1.048 to 1.092; P<0.001) were independent predictors of all cause death and HR of SOFA score was the highest in these parameters. Incorporating SOFA score into GWTG-HF score yielded a significant NRI (0.528 (95% CI 0.291 to 0.765) and IDI (0.046 (95% CI 0.020 to 0.072). In DCA, compared with the reference model, the net benefit for SOFA score model was greater across the range of threshold probabilities.
Conclusions
The SOFA score, simple and validated mortality risk score can predict long-term all-cause mortality in patients with acute HF. Discriminative performance metrics such as NRI, IDI and DCA were improved on incorporation of the SOFA score for prediction of mortality.
Collapse
Affiliation(s)
- D Aoyama
- University of Fukui Hospital, Fukui, Japan
| | | | | | - Y Shiomi
- University of Fukui Hospital, Fukui, Japan
| | - H Ikeda
- University of Fukui Hospital, Fukui, Japan
| | - N Tama
- University of Fukui Hospital, Fukui, Japan
| | - Y Fukuoka
- University of Fukui Hospital, Fukui, Japan
| | - K Hasegawa
- University of Fukui Hospital, Fukui, Japan
| | - K Kaseno
- University of Fukui Hospital, Fukui, Japan
| | - K Ishida
- University of Fukui Hospital, Fukui, Japan
| | - S Miyazaki
- University of Fukui Hospital, Fukui, Japan
| | - H Uzui
- University of Fukui Hospital, Fukui, Japan
| | - H Tada
- University of Fukui Hospital, Fukui, Japan
| |
Collapse
|
26
|
Tada H, Yamagami K, Nishikawa T, Nohara A, Kawashiri M, Takamura M. P6199Lipoprotein(a) and risk of chronic kidney disease among 4,235 Japanese hospitalized patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Lipoprotein (a) [Lp(a)] has been shown to be associated with the development of chronic kidney disease (CKD) among various ethnicities. In addition, recent Mendelian randomization studies have suggested that Lp(a) seems to be causally associated with CKD. However, few data exist regarding this issue among Japanese population.
Purpose
We aimed to investigate the association between serum Lp(a) and the CKD among Japanese population.
Methods
We retrospectively investigated 6,130 subjects whose serum Lp(a) had been measured for any reason (e.g. any operations which needs bed rest for a long duration, risk factors for atherosclerosis such as hypertension or diabetes) at our University Hospital from April 2004 to March 2014. We excluded 1,895 subjects due to the lack clinical data. We assessed their Lp(a), LDL cholesterol, HDL cholesterol, triglycerides, presence of hypertension, diabetes, chronic kidney disease, smoking, body mass index, presence of coronary artery disease (CAD), and presence of CKD (stage 3 or greater).
Results
When the study subjects were divided into 5 groups based on their CKD stage, there was a significant trend among their serum Lp(a) levels (P-trend = 2.7×10–13). Under these conditions, multiple regression analysis showed that Lp(a) was significantly associated with CKD [odds ratio (OR): 1.12, 95% confidence interval (CI): 1.08–1.17; p=1.3×10–7: per 10mg/dL)., independent of other classical risk factors, including age, gender, body mass index, hypertension, diabetes, smoking, LDL cholesterol and triglycerides. Under these conditions, Lp(a) was significantly associated with CAD [OR: 1.11, 95% CI: 1.06–1.16; p=1.7×10–6: per 10mg/dL), independent of the presence of CKD.
Conclusion
Serum Lp(a) was associated with the development of CKD independent of other classical risk factors among Japanese population as well.
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | | | | | - A Nohara
- Kanazawa University, Kanazawa, Japan
| | | | | |
Collapse
|
27
|
Tada H, Nakagawa T, Okada H, Nakahashi T, Mori M, Sakata K, Kawashiri M, Takamura M. P1535Clinical impact of carotid plaque score rather than carotid intima-media thickness on atherosclerotic cardiovascular disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Carotid intima-media thickness (cIMT) assessed by ultrasound has been widely accepted as a surrogate marker of atherosclerotic cardiovascular disease. On the other hand, carotid plaque score (cPS) reflecting throughout the carotid artery plaque burden may be better marker.
Methods
We retrospectively examined 2,035 patients who underwent carotid ultrasonography between January 2006 and December 2015 at our University Hospital. Median follow-up period was 4 years. We used Cox models that adjusted for established risk factors of ASCVD, including age, gender, hypertension, diabetes, smoking, and serum lipids to assess the association of cIMT as well as cPS with major adverse cardiac events (MACE). MACE was defined as all-cause mortality or rehospitalization for a cardiovascular-related illness
Results
During follow-up, 243 participants experienced MACE. After adjustment for established risk factors, cPS was associated with MACE (hazard ratio [HR] = 3.38 for top quintile vs. bottom quintile of cPS; 95% confidence interval [CI] 1.82 to 6.27; P-trend = 1.4×10–8), while cIMT was not (HR = 0.88, P=0.57). Addition of the cPS to established risk factors significantly improved risk discrimination (C-index 0.726 vs. 0.746; P=0.017)
Conclusion
As a marker, cPS, rather than cIMT can identify 20% of individuals who are at more than three-fold increased risk for MACE. Targeting diagnostic or therapeutic interventions to this subset may prove clinically useful.
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | | | - H Okada
- Kanazawa University, Kanazawa, Japan
| | | | - M Mori
- Kanazawa University, Kanazawa, Japan
| | - K Sakata
- Kanazawa University, Kanazawa, Japan
| | | | | |
Collapse
|
28
|
Nomura T, Sumi E, Egawa G, Nakajima S, Toichi E, Uozumi R, Tada H, Nakagawa T, Hagiwara M, Kabashima K. The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial. Trials 2019; 20:489. [PMID: 31399147 PMCID: PMC6688352 DOI: 10.1186/s13063-019-3570-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 07/11/2019] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Human papilloma viruses (HPVs) infect squamous epithelial cells and form verrucous lesions, or warts. Besides the psychosocial problems caused by the disfiguring warts, a subset of HPVs can be the primary etiologic agent for malignancies such as cervical cancer. However, there is no curative antiviral therapy for HPV infection. We recently found that the viral RNA transcription of DNA viruses requires cyclin dependent kinase 9 (CDK9) in the host cells, and that FIT039, a specific inhibitor of CDK9, suppressed the proliferation of DNA viruses such as herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, human cytomegalovirus, hepatitis virus B, and HPVs. Here, we describe a protocol to evaluate the safety and antiviral effect of FIT039 on common warts in human skin. METHODS AND DESIGN A multi-institutional, single-blind, placebo-controlled randomized phase I/II clinical trial was designed to evaluate the safety and efficacy of FIT039 on common warts on the extremities. A total of 44 adults with a primary diagnosis of verruca vulgaris on the extremities without serious comorbidities will be randomized into either the intervention group with an FIT039-releasing transdermal patch or a control group for a duration of 14 days. Outcomes will be assessed at baseline and postintervention. Participants will be further assessed at 2 months follow-up. The primary endpoint for efficacy is the resolution of the warts. The safety endpoint is the incidence of adverse events and adverse drug reactions. The secondary endpoints are changes in the dimensions of the wart, the cross-sectional area of the wart, and the number of clots within the area of the wart. DISCUSSION This study is the first to assess the efficacy of FIT039 and will contribute to the development of antiviral agents that can cure refractory common warts in immunocompromised patients. TRIAL REGISTRATION UMIN Clinical Trials, UMIN000029695 . Registered on 1 November 2017.
Collapse
Affiliation(s)
- Takashi Nomura
- Department of Dermatology, Graduate School of Medicine, Kyoto University Faculty of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| | - Eriko Sumi
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| | - Gyohei Egawa
- Department of Dermatology, Graduate School of Medicine, Kyoto University Faculty of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| | - Saeko Nakajima
- Department of Dermatology, Graduate School of Medicine, Kyoto University Faculty of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| | - Eiko Toichi
- Department of Dermatology, Kyoto Medical Center, National Hospital Organization, 1-1 Fukakusa-Mukaihata-cho, Fushimi-ku, Kyoto, 612-8555 Japan
| | - Ryuji Uozumi
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| | - Harue Tada
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| | - Takayuki Nakagawa
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| | - Masatoshi Hagiwara
- Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University Faculty of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| | - Kenji Kabashima
- Department of Dermatology, Graduate School of Medicine, Kyoto University Faculty of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507 Japan
| |
Collapse
|
29
|
Ikeguchi R, Aoyama T, Kakinoki R, Ueda M, Kasai Y, Maekawa T, Tada H, Yamamoto M, Matsuda S, Nakamura T, Toguchida J. A clinical trial for Kienböck disease by cultured autologous multipotent mesenchymal stromal cells augmented with vascularized bone grafts: A report of five cases. J Orthop Sci 2019; 24:750-756. [PMID: 28274511 DOI: 10.1016/j.jos.2017.02.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2016] [Revised: 12/25/2016] [Accepted: 02/07/2017] [Indexed: 11/17/2022]
Affiliation(s)
- Ryosuke Ikeguchi
- Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Tomoki Aoyama
- Department of Physical Therapy, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
| | - Ryosuke Kakinoki
- Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Michiko Ueda
- Department of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan
| | - Yasuaki Kasai
- Department of Transfusion Medicine & Cell Therapy and Center for Cell and Molecular Therapy, Kyoto University Hospital, Kyoto, Japan
| | - Taira Maekawa
- Department of Transfusion Medicine & Cell Therapy and Center for Cell and Molecular Therapy, Kyoto University Hospital, Kyoto, Japan
| | - Harue Tada
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Michio Yamamoto
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Shuichi Matsuda
- Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Takashi Nakamura
- Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Junya Toguchida
- Department of Tissue Regeneration, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan; Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
| |
Collapse
|
30
|
Nishimura T, Tada H, Fukushima M. Correlation between the Lunar Phase and Tail-Lifting Behavior of Lizards ( Pogona vitticeps) Exposed to an Extremely Low-Frequency Electromagnetic Field. Animals (Basel) 2019; 9:ani9050208. [PMID: 31052293 PMCID: PMC6562989 DOI: 10.3390/ani9050208] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 04/12/2019] [Accepted: 04/17/2019] [Indexed: 12/03/2022] Open
Abstract
Simple Summary We examined the relationship between the number of tail lifts of lizards (Pogona vitticeps) and environmental factors, such as the calendar month, daily mean temperature, daily mean humidity, daily mean atmospheric pressure, lunar phase (full moon/new moon), and K index as a geomagnetic disturbance index using 16 months of data. We set up an extremely low-frequency electromagnetic field (ELF-EMF) group and a control group. In a multiple linear regression analysis, the independent determinants associated with the number of tail lifts were the full moon, the temperature, February, March, April, and May in the ELF-EMF group and March, April, May, and June in the control group. The P. vitticeps in the ELF-EMF group responded to the full moon whereas those in the control group did not. Abstract We previously showed that the agamid lizard Pogona vitticeps responded to an extremely low-frequency electromagnetic field (ELF-EMF; frequency: 6 and 8 Hz; peak magnetic field: 2.6 µT; peak electric field: 10 V/m) with tail-lifting behavior. In addition, the tail-lifting response to ELF-EMF disappeared when the parietal eyes of the lizards were covered by small round aluminum caps. This result suggests that the parietal eye contributes to light-dependent magnetoreception. In the present study, we set up an ELF-EMF group to evaluate the long-term effect of the ELF-EMF on lizards’ behavior and examine our hypothesis that exposure to ELF-EMFs increases the magnetic field sensitivity in lizards. We therefore include the lunar phase (full moon/new moon) and K index as environmental factors related to the geomagnetic field in the analysis. The number of tail lifts per individual per day was the response variable while calendar month, daily mean temperature, daily mean humidity, daily mean atmospheric pressure, full moon, new moon, and K index were the explanatory variables. We analyzed an ELF-EMF group and a control group separately. In a multiple linear regression analysis, the independent determinants associated with the number of tail lifts were the full moon, the temperature, February, March, April, and May in the ELF-EMF group and March, April, May, and June in the control group. The P. vitticeps in the ELF-EMF group responded to the full moon whereas those in the control group did not. In addition, in the ELF-EMF group, the number of tail lifts was higher on days when the K index was higher (P = 0.07) in the first period whereas there was no such tendency in either period in the control group. There is the possibility that the exposure to ELF-EMFs may increase magnetic-field sensitivity in lizards.
Collapse
Affiliation(s)
- Tsutomu Nishimura
- Institute for Advancement of Clinical and Translational Science (iACT), Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
- Translational Research Center for Medical Innovation, 1-5-4 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan.
| | - Harue Tada
- Institute for Advancement of Clinical and Translational Science (iACT), Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
| | - Masanori Fukushima
- Translational Research Center for Medical Innovation, 1-5-4 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan.
| |
Collapse
|
31
|
Sumi E, Nomura T, Asada R, Uozumi R, Tada H, Amino Y, Sawada T, Yonezawa A, Hagiwara M, Kabashima K. Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts. Clin Drug Investig 2019; 39:55-61. [PMID: 30284700 PMCID: PMC6510824 DOI: 10.1007/s40261-018-0712-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Cutaneous warts are caused by human papilloma virus (HPV) infection. FIT039, a specific inhibitor of CDK9, suppresses the proliferation of DNA viruses in vitro. Purpose We evaluated the safety, plasma concentrations, and efficacy of FIT039 delivered by single application of an adhesive skin patch on normal back skin and cutaneous warts. Patients and Methods In this placebo-controlled, dose-escalation, open-label, two-cohort phase I/II clinical trial, after a single administration of a 1% FIT039 patch, 3% FIT039 patch, or placebo on back skin, patients with cutaneous warts were treated with cryotherapy followed by a 1% FIT039 patch for 24 h in the first cohort. In the second cohort, cutaneous warts were treated with cryotherapy followed by a 3% FIT039 patch for 24 h. Adverse events and adverse drug reactions, the concentrations of FIT039, and surface area of cutaneous warts were evaluated. Results Neither irritant reactions nor symptoms related to FIT039 occurred when the FIT039 patches were applied to patients’ backs or on warts in ten patients. The concentrations of FIT039 were under 0.1 ng/ml at every time point. The median wart surface area at 1 week after application of the 1% FIT039 patch was similar to baseline, while that of the 3% FIT039 patch was smaller than baseline. Conclusion The FIT039 patch showed no topical or systemic adverse reactions when applied on normal skin or cutaneous warts. The safety and good adherence of the FIT039 patch are encouraging and support further studies to evaluate the efficacy of FIT039 in patients with cutaneous warts. Electronic supplementary material The online version of this article (10.1007/s40261-018-0712-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Eriko Sumi
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
| | - Takashi Nomura
- Department of Dermatology, Kyoto University Hospital, Kyoto, Japan
| | - Ryuta Asada
- Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan
| | - Ryuji Uozumi
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Harue Tada
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Yoko Amino
- Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Teruo Sawada
- Innovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan
| | - Atsushi Yonezawa
- Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan
| | - Masatoshi Hagiwara
- Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University Faculty of Medicine, Kyoto, Japan
| | - Kenji Kabashima
- Department of Dermatology, Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
32
|
Masuda N, Yamashita T, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. Abstract OT2-07-05: A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Docetaxel + Trastuzumab (H) + Pertuzumab (P) provided progression-free survival (PFS) and overall survival (OS) benefits in HER2-positive advanced or metastatic breast cancer (AMBC) in the CLEOPATRA study as a first-line therapy. However, long-term administration of docetaxel at a dose of 75 mg/m2 every 3 weeks in AMBC patients (pts) is difficult due to the toxicities. Eribulin mesylate (E) is a well-tolerated microtubule inhibitor, and we have reported the efficacy and safety of EHP regimen as first- and second-line therapy for AMBC in a multicenter, phase II study (JBCRG-M03/UMIN000012232). In this M06 study, we address the clinical question as to which is the better chemotherapy partner for HP as first line regimen, in terms of efficacy, toxicity and QOL.
Methods: JBCRG-M06 is a multicenter open-label randomized phase III study for HER2-positive AMBC pts who have received no prior chemotherapy except for the HER2- Antibody-Drug Conjugate (ADC). Pts will be randomized 1:1 to E (1.4mg/m2 on day 1 and 8) + H (8 mg/kg loading dose followed by 6 mg/kg) +P (840 mg loading dose followed by 420 mg) q3wks or standard taxanes (docetaxel 75mg/m2 on day1 or paclitaxel 80mg/m2 on day 1, 8 and 15) + HP q3wks. Stratification factors for randomization are; presence of visceral metastases, number of prior taxanes on perioperative adjuvant treatment, and treatment with prior anti-HER2-ADC. Primary endpoint is PFS and secondary endpoints include overall response rate, duration of response, OS, patient-reported outcomes (PRO) relating to QOL and peripheral neuropathy, new-metastases free survival, and safety. Translational research to search for biomarker for individual precision therapy will be performed. Main eligibility criteria are as follows: pts with HER2-positive AMBC, female aged 20-70 years old, ECOG PS of 0-1, LVEF ≥ 50% at baseline and adequate organ function. Pts who had progressive MBC within 6 months after the end of primary adjuvant systemic chemotherapy are excluded. The sample size was calculated by type1 error (2-sided) of 0.05 and 80% power to estimate the noninferiority margin 1.33 with an expected median PFS of 14.2 months. The target number of pts is 480 recruited over the duration of 3-years. The first patient in was achieved on August 2017. (ClinicalTrials.gov Identifier:NCT03264547).
Citation Format: Masuda N, Yamashita T, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S. A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-07-05.
Collapse
Affiliation(s)
- N Masuda
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Yamashita
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Saji
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Araki
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Ito
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Takano
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - M Takahashi
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - J Tsurutani
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - K Koizumi
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - M Kitada
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Kojima
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Y Sagara
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - H Tada
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Iwasa
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Kadoya
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - T Iwatani
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - H Hasegawa
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Morita
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - S Ohno
- NHO Osaka National Hospital, Osaka, Japan; Kanagawa Cancer Center, Yokohama, Japan; Fukushima Medical University Hospital, Fukushima, Japan; Hyogo College of Medicine, Nishinomiya, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Toranomon Hospital, Tokyo, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Kindai University Hospital, Osaka-Sayama, Japan; Seirei Hamamatsu General Hospital, Hamamatsu, Japan; Asahikawa Medical University Hospital, Asahikawa, Japan; St. Marianna University School of Medicine Hospital, Kawasaki, Japan; Sagara Hospital, Kagoshima, Japan; Tohoku University Hospital, Sendai, Japan; Hiroshima University Hospital, Hiroshima, Japan; Eisai Co., Ltd., Tokyo, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan
| |
Collapse
|
33
|
Harada N, Tada H, Miyashita M, Hamanaka Y, Sato A, Ishida T. A joint metabolic profile of plasma and tissue samples or discovering novel biomarkers in breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Okada H, Nakanishi C, Yoshida S, Shimojima M, Mori M, Yokawa J, Tada H, Hayashi K, Kawashiri M, Yamagishi M. P6556Impact of genetically corrected iPSCs on possible reduction LDL-cholesterol in homozygous familial hypercholesterolemia. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Okada
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - C Nakanishi
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - S Yoshida
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - M Shimojima
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - M Mori
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - J Yokawa
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - H Tada
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - K Hayashi
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - M Kawashiri
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| | - M Yamagishi
- Kanazawa University Graduate School of Medicine, Department of Cardiovascular and Internal Medicine, Kanazawa, Japan
| |
Collapse
|
35
|
Morishita T, Uzui H, Ishida K, Kaseno K, Miyazaki S, Fukuoka Y, Ikeda H, Tama N, Shiomi Y, Yamaguchi J, Sato Y, Aoyama D, Ishikawa E, Miyahara K, Tada H. P4730Associations of cachexia and prognosis in patients with heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4730] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - H Uzui
- University of Fukui Hospital, Fukui, Japan
| | - K Ishida
- University of Fukui Hospital, Fukui, Japan
| | - K Kaseno
- University of Fukui Hospital, Fukui, Japan
| | - S Miyazaki
- University of Fukui Hospital, Fukui, Japan
| | - Y Fukuoka
- University of Fukui Hospital, Fukui, Japan
| | - H Ikeda
- University of Fukui Hospital, Fukui, Japan
| | - N Tama
- University of Fukui Hospital, Fukui, Japan
| | - Y Shiomi
- University of Fukui Hospital, Fukui, Japan
| | | | - Y Sato
- University of Fukui Hospital, Fukui, Japan
| | - D Aoyama
- University of Fukui Hospital, Fukui, Japan
| | - E Ishikawa
- University of Fukui Hospital, Fukui, Japan
| | - K Miyahara
- University of Fukui Hospital, Fukui, Japan
| | - H Tada
- University of Fukui Hospital, Fukui, Japan
| |
Collapse
|
36
|
Nakahashi T, Sakata K, Tada H, Terai H, Horita Y, Ikeda M, Namura M, Takamura M, Hayashi K, Kawashiri M, Yamagishi M. P3672Assessment of ankle-brachial index to predict in-hospital bleeding complication and optimal duration of dual antiplatelet therapy in patients with acute coronary syndrome. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- T Nakahashi
- Kanazawa Cardiovascular Hospital, Department of Cardiology, Kanazawa, Japan
| | - K Sakata
- Kanazawa University Hospital, Division of Cardiovascular Medicine, Kanazawa, Japan
| | - H Tada
- Kanazawa University Hospital, Division of Cardiovascular Medicine, Kanazawa, Japan
| | - H Terai
- Kanazawa Cardiovascular Hospital, Department of Cardiology, Kanazawa, Japan
| | - Y Horita
- Kanazawa Cardiovascular Hospital, Department of Cardiology, Kanazawa, Japan
| | - M Ikeda
- Kanazawa Cardiovascular Hospital, Department of Cardiology, Kanazawa, Japan
| | - M Namura
- Kanazawa Cardiovascular Hospital, Department of Cardiology, Kanazawa, Japan
| | - M Takamura
- Kanazawa University Hospital, Disease Control and Homeostasis, Kanazawa, Japan
| | - K Hayashi
- Kanazawa Cardiovascular Hospital, Department of Cardiology, Kanazawa, Japan
| | - M Kawashiri
- Kanazawa Cardiovascular Hospital, Department of Cardiology, Kanazawa, Japan
| | - M Yamagishi
- Kanazawa Cardiovascular Hospital, Department of Cardiology, Kanazawa, Japan
| |
Collapse
|
37
|
Tada H, Kawashiri M, Nohara A, Inazu A, Mabuchi H, Yamagishi M. P5381Post-prandial remnant lipoprotein metabolism in sitosterolemia. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | | | - A Nohara
- Kanazawa University, Kanazawa, Japan
| | - A Inazu
- Kanazawa University, Kanazawa, Japan
| | - H Mabuchi
- Kanazawa University, Kanazawa, Japan
| | | |
Collapse
|
38
|
Tada H, Kawashiri M, Nohara A, Inazu A, Mabuchi H, Yamagishi M. P6269Remnant-like particles and coronary artery disease in familial hypercholesterolemia. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | | | - A Nohara
- Kanazawa University, Kanazawa, Japan
| | - A Inazu
- Kanazawa University, Kanazawa, Japan
| | - H Mabuchi
- Kanazawa University, Kanazawa, Japan
| | | |
Collapse
|
39
|
Tada H, Miyashita M, Gonda K, Watanabe M, Suzuki A, Watanabe G, Harada N, Sato A, Hamanaka Y, Masuda N, Toi M, Ohno S, Bando H, Ishiguro H, Inoue K, Yamamoto N, Kuroi K, Ohuchi N, Ishida T. Abstract P2-09-28: New quantitative diagnostic method by fluorescence nanoparticle for HER2 positive breast cancer treated with neoadjuvant lapatinib and trastuzumab: The Neo LaTH study (JBCRG-16TR). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-09-28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2 (human epidermal growth factor receptor 2) testing performed by IHC (immunohistochemical) methods and FISH (fluorescence in situ hybridization) is semi-quantitative. Exact quantification of HER2 is needed to predict which patients are more or less likely to response to anti HER2 therapy. To improve the method for cancer patients' HER2 status, we developed a novel fluorescence IHC method using new fluorescence nanoparticle. The fluorescent intensity of this new nanoparticles, termed phosphor-integrated dot (PID), was approximately 100-fold brighter than that of Quantum dots. Because of its increased brightness and analyzing technology, this PID-based fluorescent IHC(IHC-PIC) has an ability of quantifying the biomarker protein in the cancer tissue sample at single particle level. In this study, the primary objective was to investigate if pathological complete response (pCR) rate in HER2- positive breast cancer treated by trastuzumab and lapatinib containing neoadjuvant systemic therapy would depend on the level of HER2, EGFR, HER3, Ki67, ER and PgR protein quantified by this new method.
Methods: The Neo-LaTH study is a randomized phase II multicenter trial evaluating the efficacy and safety of lapatinib and trastuzumab followed by lapatinib and trastuzumab plus weekly paclitaxel with or without prolongation of anti-HER2 therapy prior to chemotherapy (18 weeks vs. 6 weeks). The primary endpoint was the comprehensive pCR rate. We evaluated the HER2, EGFR, HER3, Ki67, ER and PgR amount by nano-patho method using PID in formalin-fixed paraffin-embedded core biopsy samples taken at diagnosis retrospective analysis. Univariate and multivariate analyses were performed to determine the association between pCR and variables, including HER2, EGFR, HER3, Ki67, ER and PgR nano-patho score and clinicopathological factors including histological grade, tumor status, nodal status and HER2 FISH ratio.
Results: A total of 96 tumor samples from patients were used for the present analysis.The pCR rate was 60.4%. We obtained the images of only PID signal by the image analyses, and calculated the number of PID particles in a cell and defined it as IHC-PID score that reflects the level of HER2, EGFR, HER3, Ki67, ER and PgR protein expression in cancer cells. Univariate analysis showed that HER2 IHC-PID score(p<0.0001), ER IHC-PID score(p=0.009) and PgR IHC-PID score(p=0.019) were associated with pCR and multivariate analysis showed that HER2 IHC-PID score was significantly associated with pCR (adjusted odds ratio, 0.990 [95% CI, 0.984–0.996]; P < .0001).
Conclusion: We successfully performed the quantitative IHC-PID for HER2, EGFR, HER3, Ki67, ER and PgR. And we propose using HER2 IHC-PID score as a predictive factor for trastuzumab and lapatinib containing neoadjuvant systemic therapy. This quantitative diagnostic method would be expected to contribute to the development of a molecular therapeutic strategy.
Citation Format: Tada H, Miyashita M, Gonda K, Watanabe M, Suzuki A, Watanabe G, Harada N, Sato A, Hamanaka Y, Masuda N, Toi M, Ohno S, Bando H, Ishiguro H, Inoue K, Yamamoto N, Kuroi K, Ohuchi N, Ishida T. New quantitative diagnostic method by fluorescence nanoparticle for HER2 positive breast cancer treated with neoadjuvant lapatinib and trastuzumab: The Neo LaTH study (JBCRG-16TR) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-09-28.
Collapse
Affiliation(s)
- H Tada
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - M Miyashita
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - K Gonda
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - M Watanabe
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - A Suzuki
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - G Watanabe
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - N Harada
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - A Sato
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - Y Hamanaka
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - N Masuda
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - M Toi
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - S Ohno
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - H Bando
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - H Ishiguro
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - K Inoue
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - N Yamamoto
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - K Kuroi
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - N Ohuchi
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| | - T Ishida
- Tohoku University, 1-1, Seiryo-machi, Sendai, Miyagi, Japan; Graduate School of Medicine, Tohoku University; Tohoku University Hospital; NHO Osaka National Hospital, Osaka, Japan; Graduate School of Medicine Kyoto University, Kyoto, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; International University of Health and Welfare, Narita, Chiba, Japan; Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan; Chiba Cancer Center, Chiba, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
| |
Collapse
|
40
|
Yano T, Kasai H, Horimatsu T, Yoshimura K, Teramukai S, Morita S, Tada H, Yamamoto Y, Kataoka H, Kakushima N, Ishihara R, Isomoto H, Muto M. A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget 2017; 8:22135-22144. [PMID: 28212527 PMCID: PMC5400653 DOI: 10.18632/oncotarget.14029] [Citation(s) in RCA: 74] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Accepted: 10/14/2016] [Indexed: 02/05/2023] Open
Abstract
Photodynamic therapy (PDT) showed promising efficacy for local failure after chemoradiotherapy (CRT) for esophageal cancer. However, PDT required long sun shade period. This study aimed to evaluate the safety and efficacy of PDT using second generation photosensitizer, talaporfin sodium for local failure after CRT. This was the multi-institutional non-randomized phase II study. Patients with histologically proven local failure limited within the muscularis propria after 50Gy or more radiotherapy (RT) for esophageal cancer were eligible. We set the primary endpoint as local complete response (L-CR) per patients. And, secondary endpoints were confirmed L-CR, local progression free survival (L-PFS), progression free survival (PFS), overall survival (OS), L-CR per lesions (Lesion L-CR), and confirmed Lesion L-CR. The PDT procedure commenced with intravenous administration of a 40 mg/m2 dose of talaporfin sodium followed by diode laser irradiation at a 664 nm wavelength. 26 eligible patients were enrolled and all were treated with PDT. Twenty three patients with 25 lesions were assessed L-CR after PDT; the L-CR rate per patients was 88.5% (95% CI: 69.8%-97.6%). No skin phototoxicity was observed, and no grade 3 or worse non-hematological toxicities related to PDT were observed. PDT using talaporfin sodium and a diode laser is a safe and curative salvage treatment for local failure after CRT or RT for patients with esophageal cancer.
Collapse
Affiliation(s)
- Tomonori Yano
- Department of Gastroenterology, Endoscopy division, National Cancer Center Hospital East, Kashiwa, Japan
| | - Hiroi Kasai
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Takahiro Horimatsu
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Kenichi Yoshimura
- Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, Japan
| | - Satoshi Teramukai
- Department of Biostatistics, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Japan
| | - Satoshi Morita
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Harue Tada
- Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Yoshinobu Yamamoto
- Department of Gastrointestinal Oncology, Hyogo Cancer Center, Hyogo, Japan
| | - Hiromi Kataoka
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | | | - Ryu Ishihara
- Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Disieses, Osaka, Japan
| | - Hajime Isomoto
- Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan
| | - Manabu Muto
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
41
|
Tsushima T, Kasai H, Kojima T, Hara H, Mori Y, Ishihara R, Kato K, Hironaka S, Tada H, Muto M. ECTAS: A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx697.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
Kojima T, Kasai H, Tsushima T, Hara H, Mori Y, Ishihara R, Kato K, Hironaka S, Mukai K, Kikuchi O, Enomoto K, Tada H, Uozumi R, Kawaguchi A, Muto M. A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Tada H, Nomura A, Teramoto R, Hosomichi K, Kawashiri M, Nohara A, Mabuchi H, Tajima A, Yamagishi M. 3102Comprehensive genotyping and phenotyping in patients with severe hypercholesterolemia. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.3102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Tada H, Okada H, Nakahashi T, Sakata K, Kawashiri M, Nohara A, Mabuchi H, Yamagishi M. P6240Assessments of carotid plaque burden in patients with familial hypercholesterolemia. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Kawashiri M, Higashikata T, Nohara A, Nakanishi C, Tada H, Okada H, Yamagishi M. P6242Impact of evolocumab, a PCSK9 inhibitor, withdrawing from regular ldl-apheresis therapy in patients with heterozygous familial hypercholesterolemia. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Morishita T, Uzui H, Amaya N, Kaseno K, Ishida K, Fukuoka Y, Ikeda H, Hasegawa K, Tama N, Shiomi Y, Sato Y, Miyoshi M, Kataoka T, Tsuji T, Tada H. P1550CHADS2, CHA2DS2-VASc and SYNTAX scores in the prediction of clinical outcomes in patients with acute coronary syndrome after percutaneous coronary intervention. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Funada A, Goto Y, Tada H, Teramoto R, Shimojima M, Yamagishi M. P2760Prehospital cardiopulmonary resuscitation duration and favourable neurological outcome after out-of-hospital cardiac arrest in patients without prehospital return of spontaneous circulation. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Tada H, Kawashiri M, Yamagishi M. P3457Associations between questionnaires relating to lifestyle habits and atherosclerotic cardiovascular disease in Japanese specific health checkups. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Nakahashi T, Tada H, Sakata K, Tanaka Y, Nomura A, Yakuta Y, Gamou T, Terai H, Horita Y, Ikeda M, Namura M, Takamura M, Kawashiri M, Yamagishi M. P3649Impact of extra-cardiac diseased location on long-term prognosis in patients with acute coronary syndrome who underwent percutaneous coronary intervention. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Hisazaki K, Kaseno K, Hasegawa K, Amaya N, Sato Y, Miyoshi M, Shiomi Y, Tama N, Ikeda H, Fukuoka Y, Morishita T, Ishida K, Uzui H, Tada H. P872How to predict phrenic nerve injury during cryoballoon ablation of atrial fibrillation?: Importance of the CMAP amplitude and cryoballoon temperature monitoring. Europace 2017. [DOI: 10.1093/ehjci/eux151.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|